The Surveillance and Pharmacogenomics Initiative for Adverse Drug Reactions (SAPhIRE) program is funded by the Biomedical Research Council (BMRC) of A*STAR, Singapore to improve drug safety by developing an active surveillance network for adverse drug reaction (ADR) monitoring and discovery of genomic biomarkers that are predictive of specific ADRs.
SAPhIRE seeks to strengthen collaborations among genomic and bioinformatic scientists, clinicians, health economists, and regulators to significantly aid in the translation and implementation of robust, validated pharmacogenomics biomarkers with demonstrated cost-effectiveness. We will build on the strong example of successful implementation of genetic testing for HLA*B-1502 prior to carbamazepine use in Singapore.
ADRs in Asian
This new initiative is built on the strategic partnership between BMRC and the Health Sciences Authority, as well as close collaboration with local hospitals. The SAPhIRE program is co-led by the Dr Jianjun Liu at the Genome Institute of Singapore (GIS) and Dr Liam Brunham at the Translational Laboratory for Genetic Medicine (TLGM).